Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Immunomic Therapeutics, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Immunomic Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Immunomic Therapeutics, Inc. - The report provides overview of Immunomic Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Immunomic Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Immunomic Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Immunomic Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Immunomic Therapeutics, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Immunomic Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Immunomic Therapeutics, Inc. Snapshot 5 Immunomic Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Immunomic Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Immunomic Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Immunomic Therapeutics, Inc. - Pipeline Products Glance 14 Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Immunomic Therapeutics, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Immunomic Therapeutics, Inc. - Drug Profiles 18 TriMix-DC 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ASP-4070 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cellular Immunotherapy for HIV 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Cellular Immunotherapy to Target EGFRvIII for Glioblastoma Multiforme 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 MC-LAMP-Vax 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 pp65 DC + Td 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ARA-LAMP-Vax 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 HIV-LAMP-Vax 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 TN-LAMP-vax 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Antigen mRNA Vaccine + LAMP 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 JCC-LAMP-Vax 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Multi-LAMP-Vax 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Immunomic Therapeutics, Inc. - Pipeline Analysis 34 Immunomic Therapeutics, Inc. - Pipeline Products by Target 34 Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration 35 Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type 36 Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action 37 Immunomic Therapeutics, Inc. - Recent Pipeline Updates 38 Immunomic Therapeutics, Inc. - Locations And Subsidiaries 40 Head Office 40 Other Locations & Subsidiaries 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables Immunomic Therapeutics, Inc., Key Information 5 Immunomic Therapeutics, Inc., Key Facts 5 Immunomic Therapeutics, Inc. - Pipeline by Indication, 2016 8 Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016 9 Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 10 Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 11 Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016 12 Immunomic Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 Immunomic Therapeutics, Inc. - Phase II, 2016 14 Immunomic Therapeutics, Inc. - Phase I, 2016 15 Immunomic Therapeutics, Inc. - Preclinical, 2016 16 Immunomic Therapeutics, Inc. - Discovery, 2016 17 Immunomic Therapeutics, Inc. - Pipeline by Target, 2016 34 Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016 35 Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016 36 Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 37 Immunomic Therapeutics, Inc. - Recent Pipeline Updates, 2016 38 Immunomic Therapeutics, Inc., Other Locations 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.